Purchase this article with an account.
E. Y. Chew, G. Cohen, T. Clemons, R. Milton, Age-Related Eye Disease Study Research Group; Ten-Year Estimated Progression Rates to Neovascular AMD and Central Geographic Atrophy From the Age-Related Eye Disease Study (AREDS). Invest. Ophthalmol. Vis. Sci. 2008;49(13):5065. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To provide estimated 10-year progression rates to neovascular AMD (NV AMD) and central geographic atrophy (CGA) using data from the Age-Related Eye Disease Study (AREDS).
4642 participants enrolled in AREDS were classified by a reading center based on stereoscopic color fundus photographs taken at baseline, two years following enrollment, and annually thereafter. Cases of advanced AMD (AAMD) were identified by a history of photocoagulation for neovascularization or by photographic evidence of either central geographic atrophy or neovascular AMD. AREDS included a clinical trial with participants randomized to treatment with placebo, antioxidants, zinc, or a combination of antioxidants and zinc. Stratified proportional hazards models were used to estimate the probability of progression to NV AMD or CGA based on baseline drusen status. Covariates included age, gender, smoking status, and AREDS treatment.
Participants were followed for a median of 10.5 years. The estimated percent probability of NV AMD or CGA after 10 years of follow-up, by baseline drusen size and adjusted for covariates, is shown below.Estimated cumulative incidence rates for various covariate patterns, such as age, gender, smoking, will also be provided. For example, the probability of NV AMD for a non smoker male age 55-64 with AAMD in the fellow eye and randomized to placebo is 42.3% compared with 35.4% for a similar participant randomized to one of three active treatments.
This PDF is available to Subscribers Only